Our Clinical Trials
At Valley Eye Physicians & Surgeons, our team participates in national clinical research to help advance the understanding and treatment of complex eye conditions. By joining these studies, eligible patients may gain access to new therapies while contributing to the development of future treatments that help improve vision and quality of life.
If you’re interested in participating in one of our clinical trials, please speak with our team to determine your eligibility.
Clinical Trials Currently Enrolling
Protocol AC — Diabetic Macular Edema (DME)
Phase III study sponsored by the National Eye Institute’s DRCR Network
Aflibercept versus Bevacizumab with Deferred Aflibercept for DME
This study compares the effectiveness of Eylea (Aflibercept) and Avastin (Bevacizumab) in treating swelling in the center of the retina, known as diabetic macular edema. The goal is to determine whether starting treatment with Eylea provides better outcomes than beginning with Avastin and switching to Eylea only if needed.
Main Criteria:
- Vision of 20/50 or worse
- Diabetic macular edema meeting specific criteria in at least one eye
- No treatment for DME within 4 months prior to starting the study
- No recent or anticipated retinal laser therapy within 6 months
- Not currently on dialysis or with a history of kidney transplant
Protocol AD — Diabetic Retinopathy (DR)
Phase III study sponsored by the NEI’s DRCR Network and Kowa Research Institute
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate versus Placebo
This study examines whether pemafibrate can help improve diabetic retinopathy, a condition caused by damage to the retinal blood vessels from high blood sugar. Participants must already be enrolled in the main PROMINENT study, which is investigating pemafibrate’s role in reducing heart and vascular complications.
Main Criteria:
- Participation in the main PROMINENT study
- Diagnosed diabetic retinopathy in at least one eye
Anterior Uveitis Study
Phase III study sponsored by Aldeyra Therapeutics, Inc.
A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial of ADX-102 Ophthalmic Solution
This study evaluates the safety and efficacy of ADX-102 ophthalmic solution in patients with non-infectious anterior uveitis. Up to 100 patients will be enrolled and randomly assigned to receive either ADX-102 or a placebo treatment over 4 weeks. The primary goal is to measure the reduction of inflammation in the front of the eye.
Main Criteria:
- 18 years of age or older
- Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks.
- Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using ETDRS testing.
- NO severe/serious ocular pathology in the study eye(s)
- NO active intermediate or posterior uveitis in the study eye(s).
NO previous anterior uveitis episode in the study eye, less than or equal to 4 weeks prior to screening
Clinical Trials Open But Not Enrolling
Protocol AB — Vitreous Hemorrhage from Proliferative Diabetic Retinopathy (PDR)
Phase III study sponsored by the NEI’s DRCR Network
Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from PDR
The objectives of this study are to 1) evaluate and compare visual acuity outcomes over 2 years of a prompt vitrectomy + panretinal photocoagulation (PRP) regimen and an intravitreous aflibercept regimen in eyes with VH from PDR for which intervention is deemed necessary, and 2) characterize the follow-up course for the 2 treatment regimens, including but not limited to post-operative complications for the vitrectomy group, and number of injections needed and percent requiring vitrectomy in the intravitreous aflibercept group.
Major Criteria:
- Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 months)
- Visual acuity letter score less than or equal to 78 (approximate Snellen equivalent 20/32)
- No systemic anti-vascular endothelial growth factor or pro-vascular endothelial growth factor treatment within 4 months prior to randomization
- No retinal detachment
- No diabetic macular edema
- No history of vitrectomy
Protocol W (Phase III study sponsored by NEI’s DRCR Network) on Diabetic Retinopathy (DR)
Intravitreous Anti-VEGF Treatment for Prevention of Vision-Threatening Diabetic Retinopathy in Eyes at High Risk
This randomized study tests whether intravitreous anti-VEGF aflibercept (Eylea) given to diabetic patients before progression to retinal neovascularization or proliferative diabetic retinopathy (PDR) decreases the risk of DR worsening. Subjects will be randomized to take either aflibercept (Eylea) or standard of care (sham injections). If this study demonstrates that intravitreous aflibercept treatment is effective and safe for reducing the incidence of PDR or center-involved DME (CI-DME) in eyes at high risk for these complications, it will provide a new strategy to prevent vision-threatening complications of diabetes for patients. Applying intravitreous aflibercept earlier in the course of disease (i.e., at baseline severe non-proliferative diabetic retinopathy) could reduce future treatment burden while potentially yielding similar or better long-term visual outcomes if PDR and DME are prevented.
Major Criteria:
- Severe NPDR (ETDRS level 53) according to investigator 4-2-1 rule
- Severe hemorrhages in at least 4 quadrants, or
- Definite venous beading in at least 2 quadrants, or
- Moderate IRMA in at least 1 quadrant
- Vision 20/25 or better
- No center-involved DME on OCT
- No history of DME/DR treatment in the prior 12 months and <4 prior injections at any time
- No prior PRP
Clinical Trials Completed
PEACHTREE protocol CLS1001-301 (Phase III study sponsored by Clearside Biomedical)
Non-infectious uveitis trial
This randomized study evaluates the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis. The primary outcome measure is the improvement of visual acuity in the study eye.
CEDAR protocol 150998-005 (Phase III study sponsored by Allergan) on wet AMD
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration
This randomized study tests the investigational product, abicipar, administered at baseline (day 1), weeks 4 and 8, followed by doses at 8-week or 12-week intervals through week 96, compared with 0.5 mg ranibizumab (Lucentis) administered every 4 weeks through week 100. The primary outcome measure is the improvement of visual acuity in the study eye. This investigational medication may reduce the frequency of intravitreous injections compared to monthly injections of ranibizumab.
ORBIT protocol TG-MV-018 (Phase IV study sponsored by ThromboGenics, Inc.) on VMA
Ocriplasmin Research to Better Inform Treatment (ORBIT)
This is an observational study to record clinical outcomes and safety in patients receiving JETREA® for the treatment of symptomatic vitreomacular adhesion (VMA) as per standard of care in US retina clinics.
SARIL-NIU-SATURN protocol ACT13480 (Phase III study sponsored by Sanofi) on Posterior Uveitis
A randomized, double-masked, and placebo-controlled study to evaluate the efficacy and safety of sarilumab administered subcutaneously every 2 weeks in patients with Non-infectious, Intermediate, Posterior, or Pan-Uveitis (NIU) Sarilumab (SAR153191)
This is a randomized study where the primary objective is to evaluate the efficacy of 200 mg sarilumab q2w at W16 in patients with NIU. The goal of NIU treatment is to control inflammation, prevent visual loss, and minimize progression.
NS2-02 (Phase II study sponsor Aldeyra Therapeutics, Inc.) on Anterior Uveitis
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis
The investigational medication NS2, a small-molecule aldehyde trap, may reduce inflammation by lowering aldehyde levels. Free aldehydes are thought to be associated with inflammatory diseases, including uveitis. NS2 is a non-steroidal that does not carry the same risks of prolonged corticosteroid use. The purpose of this study is to determine whether NS2 is safe and effective in the treatment of uveitis compared to the FDA-approved steroid eye drop, Pred Forte®.
Learn More About Clinical Trials
Participation in clinical research is voluntary and closely monitored. Each study follows strict safety standards established by the National Eye Institute (NEI) and the American Academy of Ophthalmology.
For more information about eligibility or active enrollment, please contact our research team.
Putting Your Eye Health First
We provide comprehensive eye care with a focus on medical and surgical treatments for complex eye conditions. Our experienced team combines experience with compassionate care to deliver personalized treatment tailored to each patient’s needs.
In addition to routine eye care, we have the resources to offer a high standard of innovative treatments, including cataract management, glaucoma care, and specialized retina and uveitis services. Using modern technology and a patient-focused approach, we strive to provide effective care and positive results.
Our mission is to provide our community with exceptional, personalized eye care. Your eye health is our priority—schedule your appointment with us today.
Visit Our Locations in Massachusetts
Ayer Location
We are on Groton Road, and parking is available outside the clinic. We look forward to welcoming you!
- 978-772-4000
- 979-772-3066
- 190 Groton Rd., Suite 240
- Ayer, MA 01432
Our Hours
Marlboro Location
You can find us across from the Marlboro Animal Hospital. Contact us to schedule your appointment today!
- 508-496-9000
- 508-486-9001
- 420 Lakeside Ave., Suite 103
- Marlboro, MA 01752
Our Hours
Worcester Location
We are on Eastern Avenue, and parking is available around the clinic. Our team is looking forward to seeing you!
- 508-552-0066
- 508-753-1677
- 2 Eastern Ave
- Worcester, MA 01613
Our Hours
About Us
Specialty Eye Care
Marlboro Location
- 420 Lakeside Ave., Suite 103
- Marlboro, MA 01752
- Phone: 508-496-9000
- Fax: 508-486-9001